Further studies need to be conducted in order to shed light on the many questions that need answering, including the identification of the most appropriate HuR mRNA targets in pancreatic cancer, the efficacy of HuR inhibition as a monotherapy or in combination with chemotherapy and the careful investigation of its mechanism of action, as blocking HuR (e.g., in combination with gemcitabine) could probably have an adverse result in PDA patients. This evidence concerns the gene ELAVL1 and pancreatic neoplasm.